RE:AstraZeneca paid USD$ 5.5 Billion to co-market Enhertu August 23, 2022 - AstraZeneca is on the hunt for M&A deals amid the contraversy the company has seen over it's Covid 19 vaccine Vaxzevria business, involving production and delivery delays in Europe, and fears over rare blood clots.
Now Astrazeneca is on the hunt for small and mid-sized acquisitions to bolster its business in cardiovascular disease and cancer, and the company is weighing on whether to stick with vaccines at all. The British drugmaker’s vaccine business could be on the way out, CEO Pascal Soriot told Reuters this pastTuesday.
AstraZeneca is also looking for "external opportunities,” Soriot told the news service. The drugmaker is eying bolt-on deals, which could include small and mid-sized companies well-versed in the oncology and cardiovascular arenas, he added.
https://www.fiercepharma.com/pharma/astrazeneca-ceo-cant-be-sure-covid-shot-vaxzevrias-future-company-weighs-wider-split